Compare FSI & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | GANX |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 88.6M |
| IPO Year | 2000 | 2021 |
| Metric | FSI | GANX |
|---|---|---|
| Price | $5.50 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 22.3K | ★ 473.3K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,494,325.00 | $55,180.00 |
| Revenue This Year | $63.39 | N/A |
| Revenue Next Year | $43.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.85 | $1.53 |
| 52 Week High | $11.48 | $4.34 |
| Indicator | FSI | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 57.60 |
| Support Level | $5.24 | $1.64 |
| Resistance Level | $5.52 | $2.05 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 63.83 | 48.44 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.